Результаты поиска

From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia.

Acute myeloid leukemia (AML) is a heterogeneous group of clonal disorders characterized by abnormal proliferation of undifferentiated myeloid progenitors, impaired hematopoiesis, and variable response to therapy. To date, only about 30% of adult patients with AML become long-term survivors and relapse and/or disease refractoriness are the major cause of treatment failure. Thus, this is an urgent unmet clinical need and new drugs are envisaged in order to ameliorate disease survival outcomes. Here, we review the latest therapeutic approaches (investigational and approved agents) for AML treatme

A systems-pharmacology analysis of herbal medicines used in health improvement treatment: predicting potential new drugs and targets.

For thousands of years, tonic herbs have been successfully used all around the world to improve health, energy, and vitality. However, their underlying mechanisms of action in molecular/systems levels are still a mystery. In this work, two sets of tonic herbs, so called Qi-enriching herbs (QEH) and Blood-tonifying herbs (BTH) in TCM, were selected to elucidate why they can restore proper balance and harmony inside body, organ and energy system. Firstly, a pattern recognition model based on artificial neural network and discriminant analysis for assessing the molecular difference between QEH an

When Cancer Clots: An Extensive Radiologic Analysis of Cancer-Associated Thromboembolism.

Cancer-associated thrombosis (CAT) is a leading cause of morbidity and mortality in patients with malignancy, yet its imaging manifestations extend far beyond the conventional diagnosis of deep vein thrombosis and pulmonary embolism. This comprehensive review examines the full spectrum of CAT as encountered by radiologists, from routine venous thromboembolism to unusual-site thromboses, arterial thromboembolic events, catheter-related complications, and endovascular management strategies. Patients with cancer face a four- to seven-fold increased risk of venous thromboembolism compared with the

Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms.

Aberrant signaling in myeloproliferative neoplasms may arise from alterations in genes coding for signal transduction proteins or epigenetic regulators. Both mutated and normal cells cooperate, altering fragile balances in bone marrow niches and fueling persistent inflammation through paracrine or systemic signals. Despite the hopes placed in targeted therapies, myeloid proliferative neoplasms remain incurable diseases in patients not eligible for stem cell transplantation. Due to the emergence of drug resistance, patient management is often very difficult in the long term. Unexpected connecti

The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside.

The mTOR pathway plays a central role in many cellular processes, such as cellular growth, protein synthesis, glucose, and lipid metabolism. Aberrant regulation of mTOR is a hallmark of many cancers, including hematological malignancies. mTOR inhibitors, such as Rapamycin and Rapamycin analogs (Rapalogs), have become a promising class of agents to treat malignant blood diseases-either alone or in combination with other treatment regimens. This review highlights experimental evidence underlying the molecular mechanisms of mTOR inhibitors and summarizes their evolving role in the treatment of he

Best of JACC: Case Reports From ACC.23.

This dedicated issue of JACC: Case Reports highlights the top ranked Complex Clinical Cases from the ACC 2023 Scientific Sessions. These cases were reviewed and selected by a committee of peers in the months leading up to the annual meeting. These reviewers were ACC members with no affiliation to the JACC: Case Reports Editorial Board. While the cases were presented at the meeting and included in the formal Abstract Book from ACC, they have not been published elsewhere. These cases illustrate how the ACC can be a place for cardiovascular professionals to come together to learn, grow, and share

Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities.

The use of chimeric antigen receptor T (CAR-T) cells is a significant therapeutic improvement increasing the prognosis for patients with a variety of hematological malignancies. However, this therapy has also sometimes life-threatening, complications. Therefore, knowledge of the treatment and management of these complications, especially in treatment centers and intensive care units, respectively, is of outstanding importance. This review provides recommendations for the diagnosis, management, and treatment of CAR-T cell-associated complications such as cytokine release syndrome, immune effect

Лимфоид и миэлоидное распространение после химического антигенного рецептора (CAR) T-Cell Perspy: The Patology's Perspective.

Цимерический антигенный рецептор (CAR) вливание Т-клеток привело к улучшению исхода у пациентов с лимфоболической лейкозой B, лимфомой B-клеток и множественной миеломой. Расширяется спектр гематолимфоидных аномалий после CAR-T-клетки, хотя они по-прежнему недостаточно признаются. Патологи играют ключевую роль в определении характеристик распространения гематолимфоидов после терапии Т-клеток CAR. В настоящем обзоре представлены клинические и патологические результаты общего гематолимфоидного распространения после CAR T-клеточной терапии, иллюстрируемые отдельными случаями. Обзор литературы пред

Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies.

Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy based on genetically engineered T cells derived from patients. The introduction of CAR T-cell therapy has changed the treatment paradigm of patients with B-cell lymphoid malignancies. However, challenging issues including managing life-threatening toxicities related to CAR T-cell infusion and resistance to CAR T-cell therapy, leading to progression or relapse, remain. This review summarizes the issues with currently approved CAR T-cell therapies for patients with relapsed or refractory B-cell lymphoid malignancies, inc

Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma.

Despite the availability of new therapies that have led to improved outcomes for patients with multiple myeloma, most patients will eventually relapse. With triplet and even quadruplet combination therapies becoming standard in the first and second line, many patients will have few treatment options after second-line treatment. Melflufen (melphalan flufenamide) is a first-in-class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Once inside the tumor cells, melflufen is hydrolyzed by peptidases to release alkylator molecules, wh

Совпадение в полном тексте источника
… Additional management strategies include growth factor support, platelet transfusions, and the use of romiplostim (US only) [ 63 , 64 ]. 7. …

Неделя ГЭЭ 2017 Презентации на плакате

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Повышение уровня информированности и знаний о раке в Йоханнесбурге и округах iLembe с помощью целенаправленных просветительских мероприятий на уровне общин: экспериментальное исследование.

В Южной Африке рак по-прежнему вызывает все большую озабоченность в области общественного здравоохранения, особенно в недостаточно обслуживаемых общинах, где различия в уровне информированности и доступе к медицинскому обслуживанию приводят к задержкам в диагностике. В рамках этого исследования была проведена оценка воздействия ориентированной на культурные особенности просветительской деятельности на основе адаптированного модуля исследований и просвещения по вопросам доступа к информации о раковых заболеваниях (c-CARE) в районах Йоханнесбурга и iLembe. Было проведено экспериментальное исслед

Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal.

Lenalidomide is an effective component of induction and maintenance therapy for multiple myeloma, though with a risk of secondary malignancies, including acute lymphoblastic leukemia (ALL). In contrast to therapy-related myeloid neoplasia, lenalidomide-associated lymphoblastic neoplasia remains poorly characterized. We conducted a dual institution retrospective study of 32 ALL cases that arose after lenalidomide maintenance (all B-lineage, 31/32 BCR::ABL-negative). B-cell ALL (B-ALL) was diagnosed at median 54 months (range, 5-119) after first exposure to lenalidomide and after median 42 month

16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.

Antiphospholipid syndrome (APS), an acquired autoimmune thrombophilia, is characterised by thrombosis and/or pregnancy morbidity in association with persistent antiphospholipid antibodies. The 16th International Congress on Antiphospholipid Antibodies Task Force on APS Treatment Trends reviewed the current status with regard to existing and novel treatment trends for APS, which is the focus of this Task Force report. The report addresses current treatments and developments since the last report, on the use of direct oral anticoagulants in patients with APS, antiplatelet agents, adjunctive ther

Талидомид как спасательный протокол для лечения множественной миеломы у собак: предварительные данные из многоцентрального ретроспективного исследования.

Множественная миелома (ММ) в собаках, как правило, обрабатывается сочетанием алкилирующих агентов и кортикостероидов. Однако отказ от лечения или нетерпимость, зачастую из-за кумулятивной токсичности, могут ограничить долгосрочную эффективность этих протоколов. Талидомид, иммуномодулятивный и антиангиогенный препарат, широко используемый в организме человека, по-прежнему в значительной степени не изучен в ветеринарной онкологии. В этом исследовании ретроспективно оценивалась клиническая эффективность и безопасность талидомида как спасательная терапия у собак с MM, которые отвергали стандартное

Автономная трансплантация стволовых клеток с помощью гематопоиетической гематомии для множественных склерозов в Соединенном Королевстве: A 20-year Ретроспективный анализ деятельности и гематологических результатов Британского общества трансплантации крови и мозга и клеточной терапии (BSBMTCT).

Автологическая трансплантация стволовых клеток (AHSCT) была разработана в качестве средства лечения множественных склерозов (MS) с тех пор. 1995. Соединенное Королевство one :: из наиболее активных стран Европы, осуществляющих АХСХТ для НР. Мы сообщаем об опыте Соединенного Королевства в области AHSCT для MS 364 :: пациенты, имеющие MS, которые лечатся AHSCT между 2002 и 2023. Мы представляем данные о смертности, связанной с трансплантацией (ТМР), осложнениях и эффективности АХСПП, определяемых расширенной шкалой показателей инвалидности (ЭДСС) в условиях бесперебойного выживания (ПФС) 2 годы

Hematologic Malignancies: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Association of HSV-1 and Reduced Oral Bacteriota Diversity with Chemotherapy-Induced Oral Mucositis in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Oral mucositis (OM) is a common complication of chemotherapy and remains a significant unmet need. The aim of this study was to investigate the role of oral bacteriota and HSV-1 in OM. Forty-six patients admitted for autologous hematopoietic stem cell transplantation were longitudinally evaluated for OM, Candida, HSV-1, and leukocyte count, and buccal mucosal bacterial samples were obtained during their admission period. The bacterial communities collected at the baseline and post-chemotherapy, chosen from the time with the highest severity, were analyzed by sequencing the 16S rRNA gene. Twent

Совпадение в полном тексте источника
… Patients were discharged after successful neutrophil engraftment and ≥ 4 days of platelet transfusion independency without major acute post-HSCT complications. …

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma.

Activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL), the major constituent of nongerminal center B-cell-like (non-GCB) DLBCL, is associated with poorer survival outcomes than GCB-type DLBCL. In Phase II studies, lenalidomide combined with R-CHOP (R(2)-CHOP) improved outcomes relative to historical R-CHOP in newly diagnosed DLBCL, particularly in non-GCB cases. ROBUST (CC-5013-DLC-002) is a randomized, double-blind, global, Phase III study of oral lenalidomide (15 mg, days 1-14) plus R-CHOP21 × 6 versus placebo-R-CHOP21 × 6 in patients with previously untreated ABC-type DLBCL. Sub

Abstracts of the Cell Therapy Transplant Canada 2022 Annual Conference.

On behalf of Cell Therapy Transplant Canada (CTTC), we are pleased to present the Abstracts of the CTTC 2022 Annual Conference. The conference was held in-person 15-18 June 2022, in Niagara Falls, Ontario. Poster authors presented their work during a lively and engaging welcome reception on Thursday, 16 June, and oral abstract authors were featured during the oral abstract session in the afternoon on Friday, 17 June 2022. Thirty-three (33) abstracts were selected for presentation as posters and six (6) as oral presentations. The top abstracts in each of four (4) categories, (1) Basic/Translati